EP1177171A1 - Indolsulfonamides substitues utilises comme produits antiviraux - Google Patents

Indolsulfonamides substitues utilises comme produits antiviraux

Info

Publication number
EP1177171A1
EP1177171A1 EP00929376A EP00929376A EP1177171A1 EP 1177171 A1 EP1177171 A1 EP 1177171A1 EP 00929376 A EP00929376 A EP 00929376A EP 00929376 A EP00929376 A EP 00929376A EP 1177171 A1 EP1177171 A1 EP 1177171A1
Authority
EP
European Patent Office
Prior art keywords
compounds
general formula
alkyl
defined above
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00929376A
Other languages
German (de)
English (en)
Inventor
Wolfgang Bender
Peter Eckenberg
Siegfried Goldmann
Michael Härter
Sabine Hallenberger
Jürgen Reefschläger
Jörg TRAPPE
Olaf Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of EP1177171A1 publication Critical patent/EP1177171A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles

Definitions

  • the present invention relates to new compounds which are suitable as medicaments, processes for their preparation and their use as medicaments, in particular as antiviral agents.
  • ⁇ , ⁇ -Naphthyl linked phenylsulfonamides are mainly known from phototechnical publications [see see JP-06 122 669-A2, EP-684 515-A1; JP-59 174 836-A2, DE-2 902 074, US-3 925 347, US-4 035 401, US-3 622 603, US-3 482 971. EP-284 130].
  • WO 90/09 787 discloses sulfonamides as radio- or chemosensitizers and their use in the treatment of tumors.
  • the invention relates to compounds of the general formula (I)
  • R 1 represents a group selected from the following formulas
  • R 3 represents hydrogen, (C 1 -C 6 ) alkyl or (C 3 -C 6 ) cycloalkyl, each of which can be substituted by 1 to 3 substituents selected from the group consisting of hydroxyl, halogen, amino , Mono- or di (C 1 -C 6 ) alkylamino, (C 1 -C 6 ) alkanoylamino, (C 1 -C 6 ) alkanoyloxy, (C r C 6 ) alkanoyl, carboxy, (C r C 6 ) alkoxy - carbonyl, carbamoyl, mono- or di (C 1 -C 6 ) alkylaminocarbonyl and cyano, or
  • R 3 represents (C 6 -C 10 ) arylsulfonyl, (C 6 -C 10 ) arylcarbonyl, the (C 6 -
  • C 10 ) aryl group can in each case be substituted by 1 to 3 substituents which are selected from the group consisting of halogen, (C 1 -C 3 ) alkyl, carboxy, (C 1 -C 3 ) alkoxycarbonyl, carbamoyl,
  • R 3 represents (C r C 6 ) alkanoyl, (C 1 -C 6 ) alkylsulfonyl, (C 3 -C 6 ) cycloalkylcarbonyl, camphorsulfonyl or (C 3 -C 6 ) cycloalkylsulfonyl, or
  • R 3 represents R 4 -X-CO- or R 4 -X-CS-, wherein
  • X is O, S, NR, where R is hydrogen or (C
  • R 4 represents (C r C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl, (C 6 -C 10 ) aryl or 5- to 10-membered heteroaryl, and R for
  • R 6 is (C 2 -C 6 ) alkenyl or (C r C 8 ) alkyl, which is optionally one to three times the same or different by amino, protected amino, (C 1 -C 4 ) alkylamino, hydroxy, cyano, halogen, Azido, nitro, trifluoromethyl, carboxyl or phenyl is substituted, with phenyl in turn up to two, the same or different
  • ⁇ 0 ⁇ RR 1 ' 1 stands, wherein a represents the number 1 or 2,
  • R 8 is hydrogen, 5
  • R 9 is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl or hydrogen, or (C r C 8 ) alkyl,
  • (C r C 8 ) alkyl is optionally substituted by 10 cyano, methylthio, hydroxy, mercapto, guanidyl or by a group of the formula -NR I2 R 13 or R 14 -OC-,
  • R 12 and R 13 independently of one another are hydrogen, (C r C 8 ) alkyl or phenyl,
  • R M is hydroxy, benzyloxy, (C 1 -C 6 ) alkoxy or the group -NR 12 R 13 listed above
  • the (C r C 8 ) alkyl is optionally substituted by a 5- to 6-membered nitrogen-containing heterocycle or by indolyl, in which the corresponding -NH functions are optionally substituted by (C 1 -C 6 ) alkyl or protected by an amino protecting group are,
  • R 10 and R 11 are identical or different and denote hydrogen or an amino protecting group
  • R 7 represents hydrogen or a radical of the formula
  • R 8 ' , R 9' , R 10 ' and R 11' have the meaning of R 8 given above,
  • R 9 , R 10 and R are the same or different with this, and their salts.
  • the substances according to the invention can also be present as salts.
  • Physiologically acceptable salts are preferred in the context of the invention.
  • Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids. Salts are preferred with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids such as acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, Toluenesulfonic acid or naphthalenedisulfonic acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid
  • organic carboxylic or sulfonic acids such as acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethane
  • Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention.
  • metal or ammonium salts of the compounds according to the invention.
  • particular preference is given to Sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are derived from ammonia, or organic amines, such as ethylamine, di- or.
  • Triethylamine di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.
  • the invention relates to both the antipodes and the racemic forms as well as the diastereomer mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
  • (-C-Cg) alkyl generally represents straight-chain or branched-chain hydrocarbon radicals having 1 to 6 carbon atoms.
  • (C j -C 4 ) alkyl or (C j -C 3 ) alkyl in the context of the invention generally represent straight-chain or branched-chain hydrocarbon radicals having 1 to 4 or 1 to 3 carbon atoms. Examples include: methyl, ethyl , Per- pyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl and isohexyl.
  • Cycloalkyl stands for cycloalkyl group with 3 to 6 carbon atoms. Includes, for example: cyclopropyl, cyclopentyl and cyclohexyl. Cyclopropyl is preferred.
  • the (C j -C 6 ) alkoxy group as used in the present invention, and as also used in the definitions (-C-C6) alkoxycarbonyl, includes, for example, straight-chain or branched chain alkoxy groups with 1 to
  • alkoxy groups with 1 to 4 carbon atoms ((C j -C 4 ) alkoxy), more preferably alkoxy groups with 1 to 3 carbon atoms ((C j -C 3 ) alkoxy).
  • methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, hexoxy and isohexoxy can be mentioned.
  • Methoxy, ethoxy and propoxy are preferred.
  • mono- or di (-CC) alkylamino includes those whose alkyl groups have 1 to 6 carbon atoms. This can be symmetrical or asymmetrical alkylamino groups, such as dimethylamino, diethylamino, methylethylamino etc. This also applies to the mono- or di (-C-C 6 ) alkylamino part in the mono- or di (C j -C 6 ) Alkylaminocarbonyl group.
  • (C 6 -C ⁇ 0 ) aryl in the context of the invention is an aromatic radical having 6 to 10 carbon atoms.
  • Preferred aryl radicals are phenyl and naphthyl.
  • 5- to 10-membered heteroaryl stands for rings containing 5- to 10-membered heteroatoms, which may contain 1 to 8 heteroatoms in the ring, which are selected from O, S and N and include, for example, a pyridyl. Furyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, triazolyl.
  • 5- to 6-membered nitrogen-containing heterocycles include, for example: pyrolidine, piperidine, piperazine, morpholine, pyridyl, furyl, thienyl, pyrolyl, imidazolyl,
  • Halogen in the context of the invention includes fluorine, chlorine, bromine and iodine. Chlorine or fluorine are preferred.
  • (Ci-Cg) alkanoyl and (C ] -C 6 ) alkanoyl in the definition (C ⁇ -Cg) alkanoyloxy and (C j -Cg) alkanoylamino stands for straight-chain or branched chain alkanoyl with 1 to 6 carbon atoms in the context of the invention. Examples include: formyl, acetyl, propanoyl, butanoyl, pentanoyl, pivaloyl and hexanoyl.
  • alkanediyl group with up to 6 carbon atoms denotes straight-chain or branched-chain hydrocarbon groups which are linked to other radicals at two positions.
  • alkanediyl groups are: -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 -, -C (CH 3 ) 2 -CH 2 -, -CH (CH 3 ) -CH 2 -, -C ( CH 3 ) 2 - CH 2 -CH 2 -, -CH (CH 3 ) -CH 2 -CH 2 - etc.
  • Amino protecting groups in the context of the invention are the usual ones in the peptide—
  • These preferably include: benzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl,
  • the invention includes compounds of the formulas
  • R 1 and R 2 have the meaning given above.
  • the invention includes compounds of the general formula (I) in which:
  • R 1 represents a group selected from the formulas:
  • R 3 has the meaning given above, and their salts.
  • the invention includes compounds of general formula (I) in which:
  • R 3 represents hydrogen, (C r C 6 ) alkyl or (C r C 6 ) alkanoyl
  • R 6 is (C 1 -C 8 ) alkyl, which is optionally substituted by halogen or hydroxy, and
  • R 7 is hydrogen
  • the invention includes compounds of the general formula (I) in which R 6 is tert-butyl, which is optionally substituted by halogen or hydroxyl, and their salts.
  • the invention further relates to processes for the preparation of the compounds of formula (I).
  • R 2 is as defined above to give compounds of general formula (I).
  • the reaction is preferably carried out in the presence of bases such as pyridine, triethylamine and Hunig base etc.
  • the reaction is preferably carried out in a solvent such as tetrahydrofuran, 1,4-dioxane, dichloromethane, etc.
  • the reaction is preferably carried out in a temperature range from -10 ° C to 70 ° C.
  • the reaction is preferably carried out at normal pressure.
  • R 2 is as defined above, and
  • R a represents a group selected from the following formulas:
  • R 3 is as defined above and A is a conventional leaving group, in a manner known per se in the presence of a base to give compounds of the general formula (Ib):
  • R 2 is as defined above and R 1b represents a group selected from the following formulas:
  • R 3 is as defined above.
  • Halogen e.g. chlorine, bromine, iodine
  • OTs Tosyl
  • OMes Mesyl
  • Bases preferred in the reaction are tertiary amines such as pyridine, Hunig base, etc., alkali metal hydroxide and alkali metal carbonate.
  • the reaction is preferably carried out in inert solvents such as tetrahydrofuran, 1,4-dioxane, dichloromethane, dimethylformamide etc.
  • the reaction is preferably carried out in a temperature range from -10 ° C to 100 ° C.
  • R 2 is as defined above and R 1c is a group selected from the following formulas:
  • R 1d represents a group selected from the following formulas:
  • R 3 is as defined above.
  • reaction is preferably carried out in a solvent such as 1,4-dioxane or 1,2-
  • the reaction is preferably carried out in a temperature range from room temperature to the boiling point of the particular solvent at atmospheric pressure.
  • R 2 is as defined above and R 1e has the following formulas:
  • I be known per ° Wxeise in G o ° egenwartx of wat .the in at sr mi xt Alkalimxetallhyxdroxiden to compounds of formula (Ia) in order.
  • Alkali metal hydroxides include, for example, lithium hydroxide, sodium hydroxide, potassium hydroxide, etc., with lithium hydroxide being preferred.
  • the reaction is preferably carried out in homogeneous aqueous solvent systems.
  • the reaction is preferably in a temperature range from room temperature to
  • the reaction is preferably carried out at normal pressure.
  • R 2 is as defined above and R 1f has the following formulas: wherein R 3 is (CC 6 ) alkanoyl, in a manner known per se with complex metal hydrides to give compounds of the general formula (Ig):
  • R 2 is as defined above and R 1g has the following formulas:
  • R C is (C r C 6 ) alkyl.
  • Complex metal hydrides preferably used in the reaction are lithium aluminum hydride, diisobutyl aluminum hydride, etc.
  • the reaction is preferably carried out in a solvent such as tetrahydrofuran, 1,4-dioxane etc.
  • the reaction is preferably carried out in a temperature range from -50 ° C to 40 ° C.
  • the reaction is preferably carried out at normal pressure.
  • indole and indoline compounds can be represented as follows:
  • the isoindoline compounds are available, for example, according to the following scheme:
  • the sulfonyl chloride 1 is prepared, for example, according to ALBorrer, E. Chinoporos, M. Filosa, SR Herrchen, CR Petersen, CA Stern, J Org. Chem. 53, 2047 (1988).
  • the sulfonyl chloride 3 can be prepared analogously to the above reaction.
  • the production of the sulfonyl chloride 2 takes place e.g. according to P.R. Carlier, M.P. Lockshin, M.P. Filosa, J. Org. Chem. 59, 3232 (1994).
  • the compounds of the general formula (I) can then be obtained from these compounds after reaction with the amines of the formula (III), saponification of the acetyl group, for example with Li ⁇ H / H 2 ⁇ and subsequent reaction with R 3 -A.
  • the aniline 4 is produced e.g. in accordance with U.S. Patent No. 3,979,202.
  • the aniline 6 is produced e.g. according to S. Rajappa, R. Sreenivasan, A.
  • Aniline 7 is produced, for example, according to WO 9631462.
  • Aniline 8 is produced, for example, according to RW Hartmann, M. Reichert, S. Goehring, Ewr. J Med. Chem Chim. Ther. 29: 807 (1994).
  • Anilines 5 and 9 are prepared in an analogous manner.
  • the invention further relates to compounds of formula (I) for use as medicaments.
  • the invention further relates to a pharmaceutical composition which comprises a compound of the general formula (I) in admixture with at least one pharmaceutically acceptable carrier or excipient.
  • the invention further relates to the use of the compound of general formula (I) for the manufacture of a medicament.
  • the invention further relates to the use of a compound of general formula (I) for the manufacture of a medicament for the treatment of viral infections, in particular infections by cytomegaloviruses.
  • the compounds of general formulas (I) according to the invention show an unpredictable surprising spectrum of action. They show an antiviral activity against representatives of the group of herpes viridae, especially against the human cytomegalovirus (HCMV). They are therefore suitable for the treatment and prophylaxis of diseases caused by herpes viruses, in particular diseases caused by human cytomegalovirus (HCMV).
  • the anti-HCMV activity was determined in a screening test system in 96-well microtiter plates with the aid of human embryonic lung fibroblasts (HELF) cell cultures determined.
  • the influence of the substances on the spread of the cytopathogenic effect was determined in comparison to the reference substance ganciclovir (Cymevene R sodium), a clinically approved anti-HCMV chemotherapeutic agent (EC 50 , corresponding to the effective concentration at which 50% inhibition of virus activity is achieved).
  • the cell lawn in the substance-free virus controls is completely destroyed by the cytopathogenic effect of HCMV (100% CPE).
  • the plates are evaluated using a projection microscope (plaque viewer).
  • the compounds according to the invention are therefore valuable active substances for the treatment and prophylaxis of diseases which are triggered by human cytomegalovirus.
  • the following can be mentioned as indication areas: 1) Treatment and prophylaxis of HCMV infections in AIDS patients (retinitis, pneumonitis, gastrointestinal infections).
  • mice 5 week old male mice, strain NOD / LtSz-Prkdc (scid) / J, were obtained from a commercial breeder (The Jackson Lab., Bar Harbor). The animals were kept in isolators under sterile conditions (including bedding and feed).
  • Murine cytomegalovirus (MCMV), Smith strain, was passaged in vivo (BALB / c) and purified by fractional centrifugation. The titer was examined using a plaque assay for primary embryonic mouse fibroblasts.
  • mice were infected with a dose of 5 ⁇ 10 5 pfu in a total volume of 0.2 ml intraperitoneally. This dose leads to death in 100% of the infected animals after about 1 1 days. Treatment / evaluation
  • mice 24 hours after infection, the mice were treated with substance orally twice daily (morning and evening) over a period of 8 days.
  • the dose was 25 mg / kg body mass, the application volume 10 ml / kg body mass.
  • the substances were formulated in the form of a 0.5% tylose suspension. 16
  • Genomic DNA was purified from 25 mg of the tissue by phenol / chloroform extraction. The DNA was quantified photometrically and using the
  • the MCMV-DNA was quantified by means of DNA dot blot hybridization.
  • a digoxygenin-labeled (Boehringer-Mannheim, also listed buffer, unless otherwise described) 1.2 kb fragment from the MCMV range, Smith, Hindlll J, was used as the probe.
  • the signals were detected by means of chemiluminescence.
  • the membrane was washed in 1 x digoxygenin washing buffer 1 for 3 minutes. The filters were then incubated for 30 minutes at room temperature with shaking in 1 x digoxygenin blocking solution.
  • the filters were then incubated for 30 minutes in 20 ml / 100 cm 2 membrane with the anti-DIG alkaline phosphatase conjugate solution (1: 20000 in 1 x digoxygenin blocking solution). 2 washing steps each lasting 15 minutes with 1 x digoxygenin washing buffer followed. This was followed by 5 minutes of equilibration of the filters in 1 x digoxygenin detection buffer and detection by means of 1 ml / 100 cm 2 membrane area 1: 100 diluted CDP-Star solution. After spreading out the CDP-Star solution and incubating for 5 minutes in a dark box, the chemiluminescence was detected or evaluated using X-ray film (Kodak) or
  • Lumilmager (Boehringer Mannheim). All results were backed up statistically (analysis of variance using statistics; StatSoft Inc.).
  • the new active ingredients can be converted in a known manner into the customary formulations, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents.
  • the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.
  • the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. if water is used as the diluent, organic solvents can optionally be used as auxiliary solvents.
  • the application is carried out in the usual way, preferably orally, parenterally or topically, in particular perlingually, intravenously or intravitally, optionally as a depot in an implant.
  • solutions of the active ingredients can be used using suitable liquid carrier materials.
  • N-Acetyl-indoline-5-sulfonyl chloride was obtained using literature methods (AL Borrer, E. Chinoporos, M. Filosa, SR Herrchen, CR Petersen, CA. Stern, J. Org. Chem. 53, 2047 (1988)) as well as N -Acetyl-indoline-6-sulfonyl chloride (PR Carlier, MP Lockshin, MP Filosa, J. Org. Chem. 59,
  • N-acetyl-isoindoline-5-sulfonyl chloride was prepared from N-acetylisoindoline and chlorosulfonic acid in analogy to N-acetyl-indoline-5-sulfonyl chloride.
  • N- (N-Acetylindolin-5-sulfonyl) -N '- (3-fluoro-2,2-dimethylpropanoyl) -l, 3-diaminobenzene A solution of 3.50 g (16.65 mmol) of N-3-fluoro-2,2-dimethylpropanoyl) -l, 3-diaminobenzene in 10 ml of dry THF was added dropwise to a solution of 3.93 g (15 , 13 mmol) of N-acetyl-indoline-5-sulfonyl chloride and 5.99 g (75.67 mmol) of pyridine in 50 ml of dry THF at 0 ° C. The ice bath was removed and stirring was continued at room temperature for 24 hours. Then that became
  • N-ethylindoline and isoindoline sulfonamides of Examples 15, 20, 35, 30, 34, 8, 11, 27, 46, 41, 40, 62, 60 and 57 of the following table were obtained in the same way.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés convenant comme médicaments, leur procédé de production et leur utilisation comme médicaments, notamment comme produits antiviraux.
EP00929376A 1999-04-30 2000-04-18 Indolsulfonamides substitues utilises comme produits antiviraux Withdrawn EP1177171A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19919793 1999-04-30
DE19919793A DE19919793A1 (de) 1999-04-30 1999-04-30 Neue Sulfonamide
PCT/EP2000/003492 WO2000066553A1 (fr) 1999-04-30 2000-04-18 Indolsulfonamides substitues utilises comme produits antiviraux

Publications (1)

Publication Number Publication Date
EP1177171A1 true EP1177171A1 (fr) 2002-02-06

Family

ID=7906475

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00929376A Withdrawn EP1177171A1 (fr) 1999-04-30 2000-04-18 Indolsulfonamides substitues utilises comme produits antiviraux

Country Status (7)

Country Link
US (1) US6498183B1 (fr)
EP (1) EP1177171A1 (fr)
JP (1) JP2002543180A (fr)
AU (1) AU4748900A (fr)
CA (1) CA2371621A1 (fr)
DE (1) DE19919793A1 (fr)
WO (1) WO2000066553A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053813A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung von Sulfonamiden
BRPI0614340A2 (pt) * 2005-08-17 2011-04-12 Wyeth Corp indóis substituìdos e métodos de seu uso

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925347A (en) 1967-07-24 1975-12-09 Polaroid Corp Processes of synthesizing azo compounds
US3482971A (en) 1967-07-24 1969-12-09 Polaroid Corp Scavengers for oxidized developing agent
US4035401A (en) 1970-03-30 1977-07-12 Polaroid Corporation Intermediates for photographic dyes
JPS5499433A (en) 1978-01-20 1979-08-06 Konishiroku Photo Ind Co Ltd Dye image formation method
JPS59174836A (ja) 1983-03-25 1984-10-03 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
AU567140B2 (en) 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
DE3626309A1 (de) 1986-08-02 1988-02-18 Stockhausen Chem Fab Gmbh Antivirusmittel
EP0284130B1 (fr) 1987-03-19 1991-06-26 Agfa-Gevaert N.V. Composés organiques pour utilisation dans un procédé de diffusion-transfert de colorant et éléments photographiques les contenant
WO1990009787A1 (fr) * 1989-02-27 1990-09-07 The Du Pont Merck Pharmaceutical Company Nouveaux sulfamides servant de radiosensibilisateurs
JPH06122669A (ja) 1991-12-28 1994-05-06 Ishihara Sangyo Kaisha Ltd ジアミノベンゼン誘導体を含有するホスホリパーゼａ２阻害剤
ZA941500B (en) 1993-03-10 1995-09-04 Lilly Co Eli Antitumor compositions and methods of treatment
EP0684515A1 (fr) 1994-05-27 1995-11-29 Eastman Kodak Company Elément et procédé photographique contenant un coupleur à haut rendement de couleurs d'image l'équipant de granulation améliorée
CA2263353C (fr) 1996-08-22 2002-04-23 Dong Wha Pharm. Ind. Co., Ltd. Derives d'arylsulfonylimidazoline agissant en tant qu'agents anti-tumoraux
CA2289517A1 (fr) 1997-05-30 1998-12-03 Nippon Kayaku Kabushiki Kaisha Nouveaux derives sulfonamides
DE19802437A1 (de) * 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
DE59905829D1 (de) * 1998-01-23 2003-07-10 Bayer Ag Neue naphthyl- und anilid-substituierte sulfonamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0066553A1 *

Also Published As

Publication number Publication date
CA2371621A1 (fr) 2000-11-09
US6498183B1 (en) 2002-12-24
AU4748900A (en) 2000-11-17
DE19919793A1 (de) 2000-11-02
WO2000066553A1 (fr) 2000-11-09
JP2002543180A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
DE19912638A1 (de) Naphthylcarbonsäureamid-substituierte Sulfonamide
EP0270947B1 (fr) 2-Aminotétralines basiques substitués
DE2228012C3 (de) Phthalidester der 6- [D(-)- a Aminophenylacetamido] -penicillansäure und Verfahren zu seiner Herstellung
DE19920790A1 (de) Bis-Sulfonamide mit anti-HCMV-Wirkung
EP0353557B1 (fr) Acide tétrahydro-1-benzo[c,d]-indolepropionique-sulfonamides
EP1049666B1 (fr) Nouveaux sulfamides a substitution par naphtyle et anilide
CH671958A5 (fr)
DE4331135A1 (de) Neue antiviral wirksame valinhaltige Pseudopeptide
DE4331134A1 (de) Neue antiviral wirksame Pseudopeptide
DE19930075A1 (de) Neue Amino- und Amidosulfonamide als antivirale Mittel
EP0589322B1 (fr) 5-Oxo-dibenzo[a,d]cyclohepta-1,4-diènes et leur utilisation comme agents rétroviraux
DE19802437A1 (de) Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
WO2002036115A1 (fr) Sulfonamides pour le traitement de maladies du systeme nerveux central
EP0062887A1 (fr) Dérivés de l'indolinone-2, procédé pour leur préparation et médicaments neuroanabolisants les contenant
DE1493672A1 (de) Verfahren zur Herstellung von Benzolsulfonylharnstoffen
EP1177171A1 (fr) Indolsulfonamides substitues utilises comme produits antiviraux
DE19934321A1 (de) Naphthyl-substituierte Sulfonamide
DE19927415A1 (de) Indolinylharnstoffderivate
WO2001007412A1 (fr) Tetrahydroisichinolinsulfonamides a action antivirale
DE19802436A1 (de) Neue Naphthyl- und heterocyclisch-substituierte Sulfonamide
WO2001007402A1 (fr) Agents antiviraux
EP0011092A1 (fr) Dérivés d'acide alpha-aminophénylacétique utilisables dans le traitement d'inflammations et nouveaux dérivés d'acide alpha-aminophénylacétique
EP0538691A1 (fr) Tétrahydrothiophénes substitués, procédés pour leur préparation et leur application comme médicaments
DE3705149A1 (de) 9,10-dihydro-phenanthrenderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
EP0280017A1 (fr) Dérivés d'isoxazole, procédé de préparation et composition pharmaceutiques les contenant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030330

R18W Application withdrawn (corrected)

Effective date: 20030630

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT